Our PEARL study revealed a median PFS of 5.8 months, an ORR of 23.0%, and a DCR of 85.1% with pyrotinib among HER2-mutated patients with NSCLC. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.